Acute Lymphoblastic Leukemia

Abstract

Overview In adults, acute lymphoblastic leukemia (ALL) is a disease with poor prognosis. In the last several years, there have been significant advances in understanding the disease biology, prognostication, and in the development of novel therapies. These include development of monoclonal antibodies, antibody–drug conjugates, tyrosine kinase inhibitors, and more recently, chimeric antigen receptor T‐cell therapy. These therapies are beginning to result in improvements in survival of patients with ALL.